13D Filing: Elliott Associates, L.p. and Mednax Inc. (NYSE:MD)

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Elliott Associates 517,121 0 517,121 0 517,121 0.6%
Elliott International 0 1,098,879 0 1,098,879 1,098,879 1.2%
Elliott International Capital Advisors Inc 0 1,098,879 0 1,098,879 1,098,879 1.2%

Page 1 of 8 – SEC Filing

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D/A

Under the Securities Exchange Act of 1934

(Amendment No. 1)

MEDNAX, Inc.

(Name of Issuer)

Common Stock,
par value $0.01 per share

(Title of Class of Securities)

58502B106

(CUSIP Number)

Elliott Associates, L.P.

c/o Elliott Management Corporation

40 West 57th Street

New York, NY 10019

with a copy to:

Eleazer Klein, Esq.
Marc Weingarten, Esq.

Schulte Roth & Zabel LLP

919 Third Avenue

New York, New York 10022

(212) 756-2000

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

September
18, 2018

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule
13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule
13d-1(f) or Rule 13d-1(g), check the following box. [ ]

(Page 1 of 8 Pages)

______________________________

* The remainder of this cover page shall be filled out for a reporting
person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing
information which would alter disclosures provided in a prior cover page.

The information required on the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions
of the Act (however, see the Notes).

Follow Pediatrix Medical Group Inc. (NYSE:MD)

Page 2 of 8 – SEC Filing

1

NAME OF REPORTING PERSON

Elliott Associates, L.P.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) x

(b) ¨

3 SEC USE ONLY
4

SOURCE OF FUNDS

WC

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
6

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH:
7

SOLE VOTING POWER

517,121 (1)

8

SHARED VOTING POWER

0

9

SOLE DISPOSITIVE POWER

517,121 (1)

10

SHARED DISPOSITIVE POWER

0

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

517,121 (1)

12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

0.6%

14

TYPE OF REPORTING PERSON

PN

(1) Excludes cash-settled swaps disclosed in Item 6 representing
net economic exposure comparable to 862,217 additional shares of Common Stock (as defined below), which if aggregated with such
beneficially owned shares, represent an aggregate economic interest in 1,379,338 shares representing 1.5% of the outstanding shares.

Follow Pediatrix Medical Group Inc. (NYSE:MD)

Page 3 of 8 – SEC Filing

1

NAME OF REPORTING PERSON

Elliott International, L.P.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) x

(b) ¨

3 SEC USE ONLY
4

SOURCE OF FUNDS

WC

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
6

CITIZENSHIP OR PLACE OF ORGANIZATION

Cayman Islands, British West Indies

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH:
7

SOLE VOTING POWER

0

8

SHARED VOTING POWER

1,098,879 (1)

9

SOLE DISPOSITIVE POWER

0

10

SHARED DISPOSITIVE POWER

1,098,879 (1)

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

1,098,879 (1)

12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

1.2%

14

TYPE OF REPORTING PERSON

PN

(1) Excludes cash-settled swaps disclosed in Item 6 representing
net economic exposure comparable to 1,832,215 additional shares of Common Stock, which if aggregated with such beneficially owned
shares, represent an aggregate economic interest in 2,931,094 shares representing 3.1% of the outstanding shares.

Follow Pediatrix Medical Group Inc. (NYSE:MD)

Page 4 of 8 – SEC Filing

1

NAME OF REPORTING PERSON

Elliott International Capital Advisors Inc.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) x (b) ¨
3 SEC USE ONLY
4

SOURCE OF FUNDS

OO

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
6

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH:
7

SOLE VOTING POWER

-0-

8

SHARED VOTING POWER

1,098,879 (1)

9

SOLE DISPOSITIVE POWER

-0-

10

SHARED DISPOSITIVE POWER

1,098,879 (1)

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

1,098,879 (1)

12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

1.2%

14

TYPE OF REPORTING PERSON

CO

(1) Excludes cash-settled swaps disclosed in Item 6 representing
net economic exposure comparable to 1,832,215 additional shares of Common Stock, which if aggregated with such beneficially owned
shares, represent an aggregate economic interest in 2,931,094 shares representing 3.1% of the outstanding shares.

Follow Pediatrix Medical Group Inc. (NYSE:MD)

Page 5 of 8 – SEC Filing

The following constitutes Amendment No. 1 to the Schedule 13D filed by the undersigned (the “Amendment No. 1“).  This Amendment No. 1 amends the Schedule 13D as specifically set forth herein.
Item 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION
Item 3 is hereby amended and restated to read as follows:
Elliott Working Capital The aggregate purchase price of the shares of Common Stock directly owned by Elliott is approximately $23,024,559.
Elliott International Working Capital The aggregate purchase price of the shares of Common Stock directly owned by Elliott International is approximately $48,926,569.
The Reporting Persons may effect purchases of shares of Common Stock through margin accounts maintained for them with prime brokers, which extend margin credit as and when required to open or carry positions in their margin accounts, subject to applicable federal margin regulations, stock exchange rules and such firms’ credit policies. Positions in shares of Common Stock may be held in margin accounts and may be pledged as collateral security for the repayment of debit balances in such accounts. Since other securities may be held in such margin accounts, it may not be possible to determine the amounts, if any, of margin used to purchase shares of Common Stock.
Item 5. INTEREST IN SECURITIES OF THE ISSUER
Item 5(a) is hereby amended and restated to read as follows:

(a)       As
of the date hereof, Elliott, Elliott International and EICA collectively have combined economic exposure in the Issuer of approximately
4.6% of the shares of Common Stock outstanding.

The
aggregate percentage of Common Stock reported owned by each person named herein is based upon 93,466,848 shares of Common
Stock outstanding, which is the total number of shares of Common Stock outstanding as of July 27, 2018 as reported in the Issuer’s
Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2018, filed with the Securities and Exchange Commission
(the “SEC“) on August 2, 2018.

As
of the date hereof, Elliott itself and through The Liverpool Limited Partnership, a Bermuda limited partnership and a wholly-owned
subsidiary of Elliott (“Liverpool“) beneficially owned 517,121 shares of Common Stock, constituting 0.6% of the
shares of Common Stock outstanding.

As
of the date hereof, Elliott International beneficially owned 1,098,879 shares of Common Stock, constituting 1.2% of the shares
of Common Stock outstanding. EICA, as the investment manager of Elliott International may be deemed to beneficially own the 1,098,879
shares of Common Stock beneficially owned by Elliott International, constituting 1.2% of the shares of Common Stock outstanding.

Collectively,
Elliott, Elliott International and EICA beneficially own 1,616,000 shares of Common Stock, constituting approximately 1.7% of the
shares of Common Stock outstanding.

Follow Pediatrix Medical Group Inc. (NYSE:MD)

Page 6 of 8 – SEC Filing

Collectively,
Elliott, Elliott International and EICA have net economic exposure comparable to approximately 2.9% of the shares of Common Stock
outstanding pursuant to the Derivative Agreements, as disclosed in Item 6.

Item 5(c) is hereby amended and restated to read as follows:

(c)       The
transactions effected by the Reporting Persons during the past 60 days are set forth on Schedule 1 attached hereto.

Item 5(e) is hereby amended and restated to read as follows:

(e)       September
18, 2018.

Item 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER

The first paragraph of Item 6 is hereby amended and restated
to read as follows:

Elliott,
through Liverpool, and Elliott International have entered into notional principal amount derivative agreements (the “Long
Derivative Agreements
“) in the form of long cash settled swaps with respect to 886,217 and 1,883,215 shares of Common
Stock of the Issuer, respectively (representing economic exposure comparable to 0.9% and 2.0% of the shares of Common Stock of
the Issuer, respectively). Collectively, the Long Derivative Agreements held by the Reporting Persons represent economic exposure
comparable to an interest in approximately 3.0% of the shares of Common Stock. The Long Derivative Agreements provide Elliott and
Elliott International with economic results that are comparable to the economic results of ownership but do not provide them with
the power to vote or direct the voting or dispose of or direct the disposition of the shares that are referenced in the Long Derivative
Agreements (such shares, the “Subject Long Shares“). The Reporting Persons disclaim beneficial ownership in the
Subject Long Shares. The counterparties to the Long Derivative Agreements are unaffiliated third party financial institutions.
Elliott, through Liverpool, and Elliott International have entered into notional principal amount derivative agreements in the
form of cash settled swaps (the “Short Derivative Agreements”) representing short economic exposure to 24,000
and 51,000 shares of Common Stock of the Issuer, respectively (representing economic short exposure comparable to approximately
0.03% and 0.1% of the shares of Common Stock of the Issuer, respectively). Collectively, the Short Derivative Agreements held by
the Reporting Persons represent short economic exposure to approximately 0.1% of the shares of Common Stock. The Short Derivative
Agreements provide Elliott and Elliott International with economic results that are comparable to a short position and do not provide
them with the power to vote or direct the voting or dispose of or direct the disposition of the shares that are referenced in the
Short Derivative Agreements (such shares, the “Subject Short Shares”). The Reporting Persons disclaim beneficial
ownership in the Subject Short Shares. The counterparties to the Short Derivative Agreements are unaffiliated third party financial
institutions. The Long Derivative Agreements and Short Derivative Agreements (together, the “Derivative Agreements”)
provide Elliott and Elliott International with net economic exposure to an aggregate of 2,694,432 shares of Common Stock representing
net economic exposure comparable to approximately 2.9% of the shares of Common Stock of the Issuer.

Item 7. EXHIBITS
 
Exhibit Description
Schedule 1 – Transactions of the Reporting Persons Effected During the Past 60 Days

Follow Pediatrix Medical Group Inc. (NYSE:MD)

Page 7 of 8 – SEC Filing

SIGNATURES

After reasonable
inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in
this statement is true, complete and correct.

DATE: September 20, 2018

ELLIOTT ASSOCIATES, L.P.
By: Elliott Capital Advisors, L.P., as General Partner
By: Braxton Associates, Inc., as General Partner
/s/ Elliot Greenberg
Name: Elliot Greenberg
Title: Vice President
ELLIOTT INTERNATIONAL, L.P.
By: Elliott International Capital Advisors Inc., as Attorney-in-Fact
/s/ Elliot Greenberg
Name: Elliot Greenberg
Title: Vice President
ELLIOTT INTERNATIONAL CAPITAL ADVISORS INC.
By: Elliott International Capital Advisors Inc., as Attorney-in-Fact
/s/ Elliot Greenberg
Name: Elliot Greenberg
Title: Vice President

Follow Pediatrix Medical Group Inc. (NYSE:MD)

Page 8 of 8 – SEC Filing

SCHEDULE 1

Transactions of the Reporting Persons Effected
During the Past 60 Days

The following transactions were effected by Elliott Associates,
L.P. in the Common Stock during the past 60 days:

Date Security Amount of Shs.
Bought / (Sold)
Approx. price ($)
per Share
08/02/2018 Common Stock (32,000) 45.04
08/03/2018 Common Stock (31,999) 46.77
08/07/2018 Common Stock (16,000) 48.57
08/09/2018 Common Stock (5,913) 48.06
08/10/2018 Common Stock (15,417) 47.93
08/14/2018 Common Stock (1,632) 48.21
08/14/2018 Common Stock (14,368) 48.17
09/18/2018 Common Stock (14,397) 47.65
09/18/2018 Common Stock (9,600) 48.25
09/19/2018 Common Stock (49,313) 47.27
09/20/2018 Common Stock (52,240) 47.48

The following transactions were effected by Elliott Associates,
L.P. (through Liverpool) in the Common Stock during the past 60 days:

Date Security Amount of Shs.
Bought / (Sold)
Approx. price ($)
per Share
08/06/2018 Common Stock (16,000) 47.61
09/04/2018 Common Stock (16,000) 48.16

The following transactions were effected by Elliott International,
L.P. in the Common Stock during the past 60 days:

Date Security Amount of Shs.
Bought / (Sold)
Approx. price ($)
per Share
08/02/2018 Common Stock (68,000) 45.04
08/03/2018 Common Stock (68,001) 46.77
08/06/2018 Common Stock (34,000) 47.61
08/07/2018 Common Stock (34,000) 48.57
08/09/2018 Common Stock (12,566) 48.06
08/10/2018 Common Stock (32,762) 47.93
08/14/2018 Common Stock (30,532) 48.17
08/14/2018 Common Stock (3,468) 48.21
09/04/2018 Common Stock (34,000) 48.16
09/18/2018 Common Stock (20,400) 48.25
09/18/2018 Common Stock (30,593) 47.65
09/19/2018 Common Stock (104,790) 47.27
09/20/2018 Common Stock (111,009) 47.48

Follow Pediatrix Medical Group Inc. (NYSE:MD)